BioSpace1h
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
“Magic” for Those Who Can’t Take Pills: Groundbreaking HIV Treatment Achieves 98% Viral Suppression
UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...
Nature14h
Four ways COVID changed virology: lessons from the most sequenced virus of all time
The man’s case didn’t give rise to any widespread variant, but it gave Gupta, with his HIV evolution background, the idea ...
Healio18h
‘We have come a long way’: Empirical data support UNAIDS HIV incidence estimates
HIV incidence in sub-Saharan Africa has declined substantially, according to both UNAIDS estimates and empirical data pulled ...
The American Journal of Managed Care21h
Global Status of HIV/AIDS Pandemic Takes Center Stage in Opening Session
The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...
The American Journal of Managed Care21h
Addressing Long COVID Challenges in People Living With HIV
To reduce care disparities and prevent them from exacerbating among people living with HIV who have long COVID, education and ...